newsfilter
← Latest News
PR Newswire·

Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer

QTTB
  • Q32 Bio appointed José Trevejo, M.D., Ph.D., as Chief Medical Officer & Ellie Hershberger, Pharm.D., as Chief Development Officer on Sept. 14, 2026.
  • The company plans to advance its lead candidate bempikibart into a registration-directed program for severe or very severe alopecia areata in the first half of 2027.
  • Bempikibart showed encouraging results in Part B of the SIGNAL-AA program, including meaningful hair regrowth, durability in the off-drug period, & a well-tolerated safety profile.
  • Dr. Trevejo previously served as Chief Medical Officer at Enveda Therapeutics & Tarsus Pharmaceuticals, where he led the FDA approval of XDEMVY for Demodex blepharitis.
  • Dr. Hershberger previously served as Chief Development Officer at Adagio Therapeutics (now Invivyd), helping build infrastructure for global approval & a $356 million IPO.
  • Q32 Bio targets the IL-7 & TSLP pathways to re-balance adaptive immunity for alopecia areata & other autoimmune diseases.
  • The company's stock trades on Nasdaq under the ticker symbol QTTB.